Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A safe and effective replacement valve for treating severe Tricuspid Regurgitation and preventing Right Ventricle dysfunction

Project description

A novel heart valve replacement procedure

Tricuspid regurgitation (TR) is a heart valve disease associated with right ventricle dysfunction. Open-heart surgery and transcatheter valve replacement are the standard treatment, but they have long recovery times and a high mortality rate. The EU-funded Trisol System project introduces a novel transcatheter valve replacement system for treating severe TR cases, allowing cardiologists to perform a safe implant procedure in 30 minutes. The project's activities will include pre-clinical validation and a safety and efficacy clinical trial. The implementation of this system is expected to increase the number of TR patients that receive treatment and reduce hospitalisation and recovery times.

Objective

In Europe, an estimated 6.5M people are affected by heart valve disease (HVD) each year. Tricuspid regurgitation (TR) is a HVD which occurs when the tricuspid valve fails to close properly, causing blood to flow backward into the right atrium. Many cases of TR are accompanied by Right Ventricle (RV) Dysfunction. The gold standard methods for tricuspid valve diseases are standard open-heart surgery and transcatheter valve replacement. However, high-risk interventions require long recovery time long in-hospital stays and have significant hospital mortality (more than 10%). Due to the high risk related to the surgical procedure, most of the patients cannot be treated. As such, there is a significant unmet clinical need for a transcatheter solution to TR. Trisol is introducing the Trisol System, a transcatheter tricuspid valve replacement system for treating severe TR and preventing RV dysfunction. The Trisol valve is constructed out of nitinol frame with specially designed sail-like leaflet. A flexible delivery system is used to position the valve into the heart with support arms anchoring to the tricuspid physiological site. The Trisol System allows cardiologists to perform a quick and safe implant procedure (30 minutes compared to 2-4 hours of standard surgery) thus increasing the number of treated population and reducing in-hospital and recovery time. Moreover, it will increase heart performance and reduce the risk of mortality typical of open-heart surgeries. The Phase 2 project will enable Trisol to scale-up production, perform validation and verification activities including a preclinical study; and validate the safety and efficacy of the Trisol System in the First-In-Human and CE mark clinical trial.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

SME-2 - SME instrument phase 2

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

TRISOL MEDICAL LTD
Net EU contribution
€ 2 324 935,20
Address
TAVOR BUILDING ENTRANCE 2 LEVEL 3
2069202 Yokneam
Israel
SME
Yes
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost
€ 3 321 336,00